BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 12040389)

  • 1. High Frequency of Homologous Recombination in the Genome of Modified Vaccinia Virus Ankara Strain (MVA).
    Zhu LX; Xie YH; Li GD; Wang Y
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2001; 33(5):497-503. PubMed ID: 12040389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selection.
    Di Lullo G; Soprana E; Panigada M; Palini A; Erfle V; Staib C; Sutter G; Siccardi AG
    J Virol Methods; 2009 Mar; 156(1-2):37-43. PubMed ID: 19038289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marker rescue of the host range restriction defects of modified vaccinia virus Ankara.
    Wyatt LS; Carroll MW; Czerny CP; Merchlinsky M; Sisler JR; Moss B
    Virology; 1998 Nov; 251(2):334-42. PubMed ID: 9837798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transient host range selection for genetic engineering of modified vaccinia virus Ankara.
    Staib C; Drexler I; Ohlmann M; Wintersperger S; Erfle V; Sutter G
    Biotechniques; 2000 Jun; 28(6):1137-42, 1144-6, 1148. PubMed ID: 10868279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of marker gene swapping and fluorescence-activated cell sorting improves the efficiency of recombinant modified vaccinia virus Ankara vaccine production for human use.
    Di Lullo G; Soprana E; Panigada M; Palini A; Agresti A; Comunian C; Milani A; Capua I; Erfle V; Siccardi AG
    J Virol Methods; 2010 Feb; 163(2):195-204. PubMed ID: 19778556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Construction and biological characteristic for the recombinant modified vaccinia virus ankara co-expressing modified GP5 and M protein of porcine reproductive and respiratory syndrome virus].
    Zheng Q; Li P; Cao R; Hou J; Chen P
    Sheng Wu Gong Cheng Xue Bao; 2008 May; 24(5):766-73. PubMed ID: 18724695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High level protein expression in mammalian cells using a safe viral vector: modified vaccinia virus Ankara.
    Hebben M; Brants J; Birck C; Samama JP; Wasylyk B; Spehner D; Pradeau K; Domi A; Moss B; Schultz P; Drillien R
    Protein Expr Purif; 2007 Dec; 56(2):269-78. PubMed ID: 17892951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination.
    Breathnach CC; Rudersdorf R; Lunn DP
    Vet Immunol Immunopathol; 2004 Apr; 98(3-4):127-36. PubMed ID: 15010222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Design and construction of transfer vectors in order to obtain recombinant modified vaccinia virus Ankara (MVA)].
    Ferrer MF; Zanetti FA; Calamante G
    Rev Argent Microbiol; 2007; 39(3):138-42. PubMed ID: 17987847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya.
    Bejon P; Peshu N; Gilbert SC; Lowe BS; Molyneux CS; Forsdyke J; Lang T; Hill AV; Marsh K
    Clin Infect Dis; 2006 Apr; 42(8):1102-10. PubMed ID: 16575727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
    Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J
    Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain.
    Suter M; Meisinger-Henschel C; Tzatzaris M; Hülsemann V; Lukassen S; Wulff NH; Hausmann J; Howley P; Chaplin P
    Vaccine; 2009 Dec; 27(52):7442-50. PubMed ID: 19539582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microarray assay for evaluation of the genetic stability of modified vaccinia virus Ankara B5R gene.
    Laassri M; Meseda CA; Williams O; Merchlinsky M; Weir JP; Chumakov K
    J Med Virol; 2007 Jun; 79(6):791-802. PubMed ID: 17457926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants.
    Melamed S; Wyatt LS; Kastenmayer RJ; Moss B
    Vaccine; 2013 Sep; 31(41):4569-77. PubMed ID: 23928462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.
    Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
    J Infect Dis; 2009 Feb; 199(3):405-13. PubMed ID: 19061423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and isolation of recombinant MVA.
    Staib C; Drexler I; Sutter G
    Methods Mol Biol; 2004; 269():77-100. PubMed ID: 15114009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1.
    Kreijtz JH; Suezer Y; van Amerongen G; de Mutsert G; Schnierle BS; Wood JM; Kuiken T; Fouchier RA; Lower J; Osterhaus AD; Sutter G; Rimmelzwaan GF
    J Infect Dis; 2007 Jun; 195(11):1598-606. PubMed ID: 17471429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.
    Coulibaly S; Brühl P; Mayrhofer J; Schmid K; Gerencer M; Falkner FG
    Virology; 2005 Oct; 341(1):91-101. PubMed ID: 16061267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation and evaluation of a recombinant modified vaccinia virus Ankara vaccine for rabies.
    Weyer J; Rupprecht CE; Mans J; Viljoen GJ; Nel LH
    Vaccine; 2007 May; 25(21):4213-22. PubMed ID: 17434244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.